Next Article in Journal
Validation of a Fast, Robust, Inexpensive, Two-Tiered Neonatal Screening Test algorithm on Dried Blood Spots for Spinal Muscular Atrophy
Next Article in Special Issue
Editorial for Special Issue “Newborn Screening for Sickle Cell Disease and other Haemoglobinopathies”
Previous Article in Journal
Including Classical Galactosaemia in the Expanded Newborn Screening Panel Using Tandem Mass Spectrometry for Galactose-1-Phosphate
Previous Article in Special Issue
Thalassemias: An Overview
Open AccessReview

Sickle Cell Disease—Genetics, Pathophysiology, Clinical Presentation and Treatment

1
Paediatric Haematology, Evelina London Children’s Hospital, Guy’s and St Thomas NHS Trust, London SE1 7EH, UK
2
Pediatric Hematology-Oncology, University of Illinois at Chicago, Chicago, IL 60612, USA
3
Haematology, Guy’s and St Thomas NHS Trust, London SE1 7EH, UK
4
Holborn Medical Centre, GP, London WC1N 3NA, UK
5
Paediatrics Department, Basildon and Thurrock University Hospitals, NHS Foundation Trust, Basildon SS16 5NL, UK
6
Haematology and Sickle Cell Centre, London North West University Healthcare NHS Trust, London NW10 7NS, UK
7
Department of Clinical Haematology, Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford OX3 9DU, UK
*
Author to whom correspondence should be addressed.
Int. J. Neonatal Screen. 2019, 5(2), 20; https://doi.org/10.3390/ijns5020020
Received: 16 February 2019 / Revised: 7 April 2019 / Accepted: 24 April 2019 / Published: 7 May 2019
Sickle cell disease (SCD) is a monogenetic disorder due to a single base-pair point mutation in the β-globin gene resulting in the substitution of the amino acid valine for glutamic acid in the β-globin chain. Phenotypic variation in the clinical presentation and disease outcome is a characteristic feature of the disorder. Understanding the pathogenesis and pathophysiology of the disorder is central to the choice of therapeutic development and intervention. In this special edition for newborn screening for haemoglobin disorders, it is pertinent to describe the genetic, pathologic and clinical presentation of sickle cell disease as a prelude to the justification for screening. Through a systematic review of the literature using search terms relating to SCD up till 2019, we identified relevant descriptive publications for inclusion. The scope of this review is mainly an overview of the clinical features of pain, the cardinal symptom in SCD, which present following the drop in foetal haemoglobin as young as five to six months after birth. The relative impact of haemolysis and small-vessel occlusive pathology remains controversial, a combination of features probably contribute to the different pathologies. We also provide an overview of emerging therapies in SCD. View Full-Text
Keywords: sickle cell disease (SCD); pathophysiology; hydroxyurea/hydroxycarbamide; haemolysis; vaso-occlusive crisis; acute chest syndrome; end-organ damage; bone marrow transplant; anaemia; foetal haemoglobin; gene therapy for haemoglobinopathies sickle cell disease (SCD); pathophysiology; hydroxyurea/hydroxycarbamide; haemolysis; vaso-occlusive crisis; acute chest syndrome; end-organ damage; bone marrow transplant; anaemia; foetal haemoglobin; gene therapy for haemoglobinopathies
Show Figures

Figure 1

MDPI and ACS Style

Inusa, B.P.D.; Hsu, L.L.; Kohli, N.; Patel, A.; Ominu-Evbota, K.; Anie, K.A.; Atoyebi, W. Sickle Cell Disease—Genetics, Pathophysiology, Clinical Presentation and Treatment. Int. J. Neonatal Screen. 2019, 5, 20.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop